[{"id":"6227118e-f47f-4c7a-b5cc-7353c6ece1aa","acronym":"","url":"https://clinicaltrials.gov/study/NCT01684150","created_at":"2021-01-18T07:18:03.871Z","updated_at":"2025-02-25T14:33:39.564Z","phase":"Phase 1","brief_title":"A Phase 1, Open-Label, Dose-Escalation \u0026 Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK \u0026 PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving","source_id_and_acronym":"NCT01684150","lead_sponsor":"Epizyme, Inc.","biomarkers":" KMT2A","pipe":" | ","alterations":" MLL rearrangement","tags":["KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pinometostat (EPZ-5676)"],"overall_status":"Completed","enrollment":" Enrollment 51","initiation":"Initiation: 09/01/2012","start_date":" 09/01/2012","primary_txt":" Primary completion: 11/01/2015","primary_completion_date":" 11/01/2015","study_txt":" Completion: 02/01/2016","study_completion_date":" 02/01/2016","last_update_posted":"2024-03-26"},{"id":"171e6e7a-7ae1-4fff-874f-6cb21a0b852f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03701295","created_at":"2021-01-18T18:08:24.523Z","updated_at":"2024-07-02T16:35:32.967Z","phase":"Phase 1/2","brief_title":"Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement","source_id_and_acronym":"NCT03701295","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IDH1 • IDH2 • KMT2A • HOXA9 • MEIS1","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement","tags":["IDH1 • IDH2 • KMT2A • HOXA9 • MEIS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • pinometostat (EPZ-5676)"],"overall_status":"Completed","enrollment":" Enrollment 1","initiation":"Initiation: 03/06/2020","start_date":" 03/06/2020","primary_txt":" Primary completion: 12/08/2020","primary_completion_date":" 12/08/2020","study_txt":" Completion: 01/12/2021","study_completion_date":" 01/12/2021","last_update_posted":"2023-10-18"},{"id":"190ca937-3d8f-4941-8dff-e6310dcd1f85","acronym":"","url":"https://clinicaltrials.gov/study/NCT02141828","created_at":"2021-01-18T09:56:46.318Z","updated_at":"2025-02-25T14:34:47.050Z","phase":"Phase 1","brief_title":"A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene","source_id_and_acronym":"NCT02141828","lead_sponsor":"Epizyme, Inc.","biomarkers":" KMT2A","pipe":"","alterations":" ","tags":["KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pinometostat (EPZ-5676)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 05/01/2014","start_date":" 05/01/2014","primary_txt":" Primary completion: 05/01/2016","primary_completion_date":" 05/01/2016","study_txt":" Completion: 06/01/2016","study_completion_date":" 06/01/2016","last_update_posted":"2023-06-16"}]